Cargando…

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012

Most studies report on colon and rectal cancers collectively, even though biologic and prognostic differences exist between these disease entities. Here, we investigated the effects of sex, age, and ethnicity/race on rectal cancer (RC) mortality by stage focusing on differences before and after 2004...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berger, Martin D., Yang, Dongyun, Sunakawa, Yu, Zhang, Wu, Ning, Yan, Matsusaka, Satoshi, Okazaki, Satoshi, Miyamoto, Yuji, Suenaga, Mitsukuni, Schirripa, Marta, Lenz, Annika Medea, Bohanes, Pierre, Barzi, Afsaneh, Figueiredo, Jane C., Hanna, Diana L., Lenz, Heinz-Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288213/ https://www.ncbi.nlm.nih.gov/pubmed/27449091 http://dx.doi.org/10.18632/oncotarget.10696

Ejemplares similares

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
por: Suenaga, Mitsukuni, et al.
Publicado: (2020)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2018)

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib
por: Matsusaka, Satoshi, et al.
Publicado: (2020)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

Trends in colorectal cancer mortality in hispanics: a SEER analysis
por: Barzi, Afsaneh, et al.
Publicado: (2017)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
por: Sebio, Ana, et al.
Publicado: (2015)

Metabolic Syndrome Prevalence by Race/Ethnicity and Sex in the United States, National Health and Nutrition Examination Survey, 1988–2012
por: Moore, Justin Xavier, et al.
Publicado: (2017)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

1988-2012 : cultura y transición
Publicado: (2012)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
por: Osumi, Hiroki, et al.
Publicado: (2013)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

A genetic variant in Rassf1a predicts outcome in mCRC patients treated with cetuximab plus chemotherapy: results from FIRE-3 and JACCRO 05 and 06 trials
por: Sebio, A., et al.
Publicado: (2016)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
por: Volz, Nico B., et al.
Publicado: (2020)

Racial/ethnic disparities in hepatocellular carcinoma treatment and survival in California, 1988-2012
por: Stewart, Susan L, et al.
Publicado: (2016)

Fertility Preservation Discussions Between Young Adult Rectal Cancer Survivors and Their Providers: Sex-Specific Prevalence and Correlates
por: Stal, Julia, et al.
Publicado: (2022)

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

In Reply to “Fertility Preservation in Young Adult Patients With Rectal Cancer: A Few Things to Consider”
por: Stal, Julia, et al.
Publicado: (2022)

Picturing Race in the British National Health Service, 1948-1988
por: Bivins, Roberta
Publicado: (2017)

Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database
por: Barzi, Afsaneh, et al.
Publicado: (2020)

Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
por: Loupakis, Fotios, et al.
Publicado: (2013)

Trends in Chronic Kidney Disease Care in the US by Race and Ethnicity, 2012-2019
por: Chu, Chi D., et al.
Publicado: (2021)

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
por: Kano, Yoshihito, et al.
Publicado: (2023)

Trends in Insulin Use and Diabetes Control in the U.S.: 1988–1994 and 1999–2012
por: Selvin, Elizabeth, et al.
Publicado: (2016)

Expanded assessment of xenobiotic associations with antinuclear antibodies in the United States, 1988–2012
por: Dinse, Gregg E., et al.
Publicado: (2022)

Race/Ethnicity, Enrichment/Fortification, and Dietary Supplementation in the U.S. Population, NHANES 2009–2012
por: Malek, Angela M., et al.
Publicado: (2019)

Educational Inequalities in Obesity among Mexican Women: Time-Trends from 1988 to 2012
por: Perez Ferrer, Carolina, et al.
Publicado: (2014)

Rectal cancer in Luxembourg : a national population-based data report, 1988–1998
por: Scheiden, René, et al.
Publicado: (2003)

Patient Care Satisfaction and Emergency Room Utilization among Young Adult Colorectal Cancer Survivors during the SARS-CoV-2 Pandemic: Lessons Learned
por: Kagramanov, Dalia, et al.
Publicado: (2023)

Distinct Gene Expression Profiles of Proximal and Distal Colorectal Cancer: Implications for Cytotoxic and Targeted Therapy
por: Maus, Martin K.H., et al.
Publicado: (2014)

Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012
por: Zimmerman, Jack E, et al.
Publicado: (2013)

Correction: Educational Inequalities in Obesity among Mexican Women: Time-Trends from 1988 to 2012
Publicado: (2014)

Trends in medication use by body mass index and age between 1988 and 2012 in the United States
por: Randhawa, Arshdeep K., et al.
Publicado: (2017)

Trends in International Incidence of Pediatric Cancers in Children Under 5 Years of Age: 1988–2012
por: Hubbard, Aubrey K, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_28t5i9bka7n17v5nbddfhuvjpm